Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 16/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16013394 | 0.88 | MKNK1 (0.53) | MKNK1NOTUMRECQL | |
| SCHEMBL16012996 | 0.86 | MKNK1 (0.46) | MKNK1NOTUMALDH1A1LMNA | |
| SCHEMBL16013357 | 0.82 | MKNK1 (0.51) | MKNK1NOTUM | |
| SCHEMBL5458654 | 0.76 | ALDH1A1 (0.41) | NOTUMALDH1A1LMNA | |
| SCHEMBL5067504 | 0.75 | ALDH1A1 (0.40) | MKNK1NOTUMALDH1A1LMNA | |
| SCHEMBL5464890 | 0.73 | ALDH1A1 (0.42) | MKNK1NOTUMALDH1A1LMNA | |
| SCHEMBL16371212 | 0.71 | MKNK1 (0.81) | MKNK1 | |
| SCHEMBL20505765 | 0.71 | MKNK2 (0.56) | MKNK1ALDH1A1 | |
| SCHEMBL16013025 | 0.71 | MKNK1 (0.52) | MKNK1NOTUM | |
| SCHEMBL5068984 | 0.71 | MKNK2 (0.42) | MKNK1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675612-B2 | Substituted thiazolopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9675612-B2 | Substituted thiazolopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9675612-B2 | Substituted thiazolopyrimidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20160159789-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159789-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159789-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| EP-3019505-A1 | SUBSTITUTED PYRAZOLO-PYRIDINAMINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-05-18 | — | — | EP | disclosed |
| US-20160009734-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-14 | — | — | US | disclosed |
| US-20160009734-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-14 | — | — | US | disclosed |
| US-20160009734-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-14 | — | — | US | disclosed |
| EP-2964656-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-13 | — | — | EP | disclosed |
| WO-2015004024-A1 | SUBSTITUTED PYRAZOLO-PYRIDINAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015004024-A1 | SUBSTITUTED PYRAZOLO-PYRIDINAMINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014135480-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135480-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009734-A1 | SUBSTITUTED THIAZOLOPYRIMIDINES | DPYD, TYMP, THPO | MKNK1 3409/4885NOTUM 1268/4885RECQL 218/4885 |
| US-20160159789-A1 | SUBSTITUTED PYRAZOLOPYRIDINES | DPYD, PGF, VEGFA | MKNK1 2345/4885NOTUM 810/4885RECQL 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.